758
Participants
Start Date
July 5, 2018
Primary Completion Date
December 2, 2020
Study Completion Date
December 2, 2020
Liraglutide
Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
Novo Nordisk Investigational Site, Seoul
Novo Nordisk Investigational Site, Gyeonggi-do
Novo Nordisk Investigational Site, Gwangju
Novo Nordisk Investigational Site, Gyeonggi-do
Novo Nordisk Investigational Site, Gyeonggi-do
Novo Nordisk Investigational Site, Suwon
Novo Nordisk Investigational Site, Incheon
Novo Nordisk Investigational Site, Gangwon-do
Novo Nordisk Investigational Site, Daegu
Novo Nordisk Investigational Site, Busan
Novo Nordisk Investigational Site, Busan
Novo Nordisk Investigational Site, Busan
Novo Nordisk Investigational Site, Busan
Novo Nordisk Investigational Site, Busan
Novo Nordisk Investigational Site, Yangsan
Novo Nordisk Investigational Site, Busan
Novo Nordisk Investigational Site, Gyeonggi-do
Novo Nordisk Investigational Site, Seoul
Novo Nordisk Investigational Site, Daejeon
Novo Nordisk Investigational Site, Daejeon
Novo Nordisk Investigational Site, Seongnam-si
Novo Nordisk Investigational Site, Seoul
Novo Nordisk Investigational Site, Seoul
Novo Nordisk Investigational Site, Seoul
Novo Nordisk Investigational Site, Seoul
Novo Nordisk Investigational Site, Seoul
Novo Nordisk Investigational Site, Seoul
Novo Nordisk Investigational Site, Seoul
Lead Sponsor
Novo Nordisk A/S
INDUSTRY